Seer Inc
NASDAQ:SEER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Seer Inc
Other Current Liabilities
Seer Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Seer Inc
NASDAQ:SEER
|
Other Current Liabilities
$370k
|
CAGR 3-Years
7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other Current Liabilities
$2.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
|
Danaher Corp
NYSE:DHR
|
Other Current Liabilities
$1.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Waters Corp
NYSE:WAT
|
Other Current Liabilities
$532.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other Current Liabilities
$682m
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other Current Liabilities
$2.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
Seer Inc
Glance View
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 118 full-time employees. The company went IPO on 2020-12-04. The firm enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The firm's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.
See Also
What is Seer Inc's Other Current Liabilities?
Other Current Liabilities
370k
USD
Based on the financial report for Dec 31, 2025, Seer Inc's Other Current Liabilities amounts to 370k USD.
What is Seer Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-2%
Over the last year, the Other Current Liabilities growth was -19%. The average annual Other Current Liabilities growth rates for Seer Inc have been 7% over the past three years , -2% over the past five years .
